Fibrino 500 mg/5 ml (IM/IV Injection)

5 ml ampoule: ৳ 50.00 (1 x 5: ৳ 250.00)

Medicine Details

Category	Details
Generic	Tranexamic acid
Company	Eskayef pharmaceuticals ltd
Also available as	Fibrino 500 mg capsule

Indications

Prophylaxis and therapy of hemophtoes
Digestive hemorrhages
Hemorrhagic syndromes in leukaemia
Cirrhosis and hemophilia
Thrombocytopenic purpura
Accidents during thrombolytic therapy and transfusion
Prophylaxis and antihemorrhagic therapy during operations of any type and nature
Particularly in pulmonary, cardiovascular and abdominal surgery
Prophylaxis and antihemorrhagic therapy of prostatic, vesical and renal surgery
Hematurias
Prophylaxis and therapy of post-partum and puerperium hemorrhages
Hemorrhagic metrophathies
Functional menometrorrhagias
Idiopathic or IUD induced menorrhagias
To promote the formation of a fibrin capsule to wall off and inhibit the growth of ovarian tumors
To cause regression of ascites secondary to carcinoma
To reduce bleeding during surgical interventions

Pharmacology

Tranexamic acid is a substance endowed with a strong antifibrinolytic action and is 10 times more active than conventional hemostatics. It inhibits plasminogen activation and has low acute and chronic toxicity. Well-absorbed by oral route with lasting effect. Does not interfere with clotting processes.

Dosage & Administration

Adults:
- Usual dose: 500-1000 mg 3 times daily
- For prophylaxis: 0.5-1 gm orally, 500 mg by the parenteral route
- For therapy of hemorrhagic manifestations: 1-3 gm orally in divided doses
Children:
- For prophylaxis: 5-10 mg per kg of body weight orally daily
- For therapeutic purposes: Doses are doubled for oral and intravenous, intramuscular treatment is begun with 10 mg/kg
Elderly patients: No reduction in dosage is necessary unless there is evidence of renal failure

Interaction

Incompatible with solutions containing penicillins. Thrombolytic drugs like Streptokinase & Urokinase antagonize the antifibrinolytic action. Potential for thrombus formation may be increased by concomitant administration of estrogen containing drugs.

Contraindications

Known individual hypersensitivity to the product
Thromboembolic disease
Arterial and venous thrombosis
Endocavitary hemorrhages
Serious kidney failure

Side Effects

Sense of fatigue
Conjunctival irritation
Nasal blockage
Itching
Skin reddening
Exanthems
Nausea
Diarrhea
Gastric pyrosis
Postural hypotension
Hypersensitivity reactions

Pregnancy & Lactation

Tranexamic Acid should not be administered during known and presumed pregnancy. Passes into breast milk to a concentration of approximately one hundredth of the concentration in the maternal blood. An antifibrinolytic effect in the infant is unlikely.

Precautions & Warnings

Use in cases of hyperfibrinolysis
Prophylactic treatment must begin 24 hours before the operation and continue until 3-4 days after
Therapy of hemorrhages must be prolonged for at least 24 hours after manifestations have disappeared
Care in cardiopathic and hepatopathic subjects

Therapeutic Class

Anti-fibrinolytic drugs
Haemostatic drugs

Storage Conditions

Store in a dry place at 15-30°C, away from light and keep out of children's reach.